Dr. Rafi Skowronski, MD

Dr. Skowronski practices at The Cancer Center at Beth Israel Deaconess Medical Center - Physical Therapy - HOPD in Needham, Massachusetts.

Dr. Skowronski's NPI, 1790047843, was assigned on June 14, 2012. Dr. Skowronski holds North Carolina license 2015-01584.

Dr. Skowronski's primary practice is The Cancer Center at Beth Israel Deaconess Medical Center - Physical Therapy - HOPD, at 148 Chestnut St, Needham, MA 02492.

Dr. Skowronski's primary practice is The Cancer Center at Beth Israel Deaconess Medical Center - Physical Therapy - HOPD in Needham, Massachusetts. Dr. Skowronski is also affiliated with Beth Israel Deaconess Hospital-Needham. The medical group on file is Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center (HMFP). Dmand AI also links Dr. Skowronski to 3 more hospitals, 4 group practices and clinics and 4 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Skowronski practices, 9 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Skowronski's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dmand AI has Dr. Skowronski's licenses on file in 2 states: North Carolina and Massachusetts.

CMS data shows 434 Medicare services from Dr. Skowronski across 5 procedure codes in 2024, for 200 Medicare patients. Medicare paid $38,245 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 200 Medicare patients who saw Dr. Skowronski in 2024. The largest group is 75 to 84, with 82 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 28% are also on Medicaid. Their average risk score is 2.15, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Skowronski's median patient age at 77, with 55% women.

In 2024, Dr. Skowronski wrote 181 Medicare Part D claims for 79 patients. 93% of them were for generic drugs. CMS names the drug for 40 of them, across 2 drugs with 11 or more claims each, at $476 in total drug cost. In 2023, CMS named 45 claims across 3 drugs.

Dr. Skowronski accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 1 general payment to Dr. Skowronski from 1 drug or device company in 2022. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $13.